Kornimate/medical-research-clean huggingface dataset:
neural mobilization exercises on pain and central sensitization

Conditions: Lateral Epicondylitis

Summary: our study aims to investigate the effects of neural mobilization exercises on central sensitization and pain characteristics in individuals with lateral epicondylitis. enrolled participants will be randomly assigned to two groups. one group will receive routine exercises and eswt treatment, while the other group will receive neural mobilization exercises in addition to routine exercises and eswt treatment.

our study aims to investigate the effects of neural mobilization exercises on central sensitization and pain characteristics in individuals with lateral epicondylitis. enrolled participants will be randomly assigned to two groups. one group will receive routine exercises and eswt treatment, while the other group will receive neural mobilization exercises in addition to routine exercises and eswt treatment. median nerve mobilizations will be implemented as the neural mobilization exercises. all groups will receive two sessions per week and complete the process in four weeks; therefore, they will have received eight sessions by the end of the study. routine exercises and median nerve mobilizations will be implemented in every session, while eswt will be implemented once a week. median nerve mobilizations will be administered in 5 sets, each consisting of 10 repetitions per session. before and after the sessions, subjective factors related to pain will be assessed using the central sensitization scale and pain catastrophizing scale, as well as pressure pain threshold.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of lateral epicondylitis * 18-65 years old exclusion criteria: any other pathology, disease, condition, pain, surgery on the elbow, wrist, fingers, shoulder, or neck in the last year

Keywords: lateral epicondylitis
efficacy of physiotherapist-supervised rehabilitation after proximal humerus fracture

Conditions: Proximal Humeral Fracture

Summary: this study investigates the efficacy of physiotherapist-supervised training once per week during 10 weeks compared to home-based training during 10 weeks, after proksimal humerus fracture.

proximal humerus fracture is the third most common fracture in elderly people after hip and colles fracture, and are often caused by fall and osteoporosis. these fractures are highly related to morbidity and mortality among elderly people and consumes considerably health care resources. more than 70% of the proximal humerus fracture patients are over 60 years of age and 75% are female. only sparse evidence reveals to what extend the patients need rehabilitation and how it should be implemented in the treatment strategy. in denmark as well as in finland the rehabilitation after proximal humerus fractures takes place in local centers in the municipalities, and the rehabilitation offered to the patients varies significantly. currently in denmark there are no national clinical guidelines to support the rehabilitation strategy.

Eligibility criteria:
inclusion criteria: •low energy proximal humeral displaced (more than 5mm or 30 degrees) two-part fracture where fracture line emerges through the surgical (or anatomical) neck, treated non-operatively exclusion criteria: * refuse to participate in the study * younger than 60 years old * non-independent * demented * does no understand written and spoken guidance in local language * pathological fracture or previous fracture in the same proximal humerus * other operational injuries in the same upper limb * major nerve injury (e.g. complete radialis- or delta palsy) * open fracture * multi-trauma patient * fracture dislocation or head splitting fracture * undisplaced fracture * isolated tuberculum fracture * fracture has no precondition to ossify by conservative treatment (no bony contact between fracture parts or the humeral shaft is in contact with the articular surface) * treating surgeon considers patient unsuitable to attend the study on medical basis

Keywords: rehabilitation
prognosis of signet ring cells in upper digestive neoplasms

Conditions: Signet Ring Cell Carcinoma; Stomach Disease; Oesophagus; Prognostic; Case-control Study

Summary: background • a major increase in incidence of signet ring cell adenocarcinomas (adci) of the upper digestive tract in western countries * discordant results in the literature concerning the prognosis value of the presence of signet ring cells. * preliminary data suggesting (i) an advanced stage at time of diagnosis, (ii) more often in the form of carcinose, (iii) a more pejorative prognosis, (iv) a recurrence more frequent, more quickly, and more often in the form of peritoneal carcinose, (v) a chemo resistance (vi) the need for a specific therapeutic strategy compared to non-signet ring cell adenocarcinomas. primary objective to test the hypothesis that 5-year survival rate is significantly lower in the signet ring cells (src) adenocarcinoma when compared to non-src adenocarcinoma in the upper digestive tract secondary objectives * impact of neoadjuvant ct on overall survival * impact and differential diagnostic value of linitis * r0 resection rates * 3 years recurrence free survival * overall 3 years survival * prognostic factors * prognostic value of the presence of a minority quota of signet ring cell * objective response rate after medical treatment (chemotherapy, radiochemotherapy) in non-resected patients * tolerance of (radio) chemotherapy for adci methodology intention to treat retrospective case-control multicentric study a pairing on demographic criteria (age, sex, asa score, center) and tumor criteria (tnm stage) will be done to ensure comparability in case control study groups. inclusion criteria all consecutive patients taken care of, for a proven histologically adenocarcinoma (adci and adnci) of the esophagus, the esogastric junction, or the stomach, in surgical or medical oncology investigator centers, will be saved in a given database. for whom the first consultation took place between january 1997 and january 2010 exclusion criteria histological type other than adenocarcinoma other localization than esogastric junction, esophagus or stomach planned study period the data will be collected over a period from january 1997 to january 2010. the objective is to complete the data collection for summer 2010.

stomach cancer signet ring cell carcinoma prognosis chemotherapy

Eligibility criteria:
inclusion criteria: * all consecutive patients taken care of, for a proven histologically adenocarcinoma (adci and adnci) of the esophagus, the esogastric junction, or the stomach, in surgical or medical oncology investigator centers, will be saved in a given database. * for whom the first consultation took place between january 1997 and january 2010 * as they benefit from a medical and/or surgical support (primitive cancer being or not resected), whatever the metastatic or the recurrence situation was. exclusion criteria: * histological type other than adenocarcinoma * other localization than esogastric junction, esophagus or stomach

Keywords: stomach disease signet ring cell carcinoma chemotherapy prognostic
simplification and test and treat strategies towards hepatitis c eliminationplatform" in china(stat)

Conditions: Hepatitis C Virus Infection

Summary: the present study aims to establish a " one-sample testing platform " and assess the prevalence of hepatitis c in individuals taking routine physical examination or outpatient visit in mainland china.

investigators intend to establish a one-sample testing platform to improve diagnosis and linkage to care process in participants under routine physical examination or outpatient visit. the platform is based on rapid diagnostic tests (rdts) for hcv screening and hcv core antigen for confirmation. rdts was used to screen for anti-hcv antibodies. the result of rdt will be interpreted within 15 minutes with the sensitivity of 98.9% (95%ci, 94.5% to 99.8%) and specificity of 98.9% (95%ci, 97.5% to 99.9%) using whole blood or finger-stick blood sample \[3-5\]. hcv core antigen is a marker of hcv replication and has a good correlation with hcv rna in hcv-positive patients (r=0.98). a recent study suggested hcv core antigen testing could be used alternative testing for hcv rna testing for diagnosis when hcv rna testing was unavailable. the process of hcv core antigen test only takes 2-3 hours. "one-sample" means only one drop (10ul) of finger-stick blood or residual blood samples from other routine tests collected from patients was needed for anti-hcv antibody testing and hcv core antigen testing, which means they will not have to take another venepuncture. in addition, the use of rdt and hcv core antigen are also less costly. this approach might improve access to care, particularly in low-income and middle-income countries. the present study aims to establish a " one-sample testing platform " in several medical institution to assess the prevalence of hepatitis c in individuals taking routine physical examination and further promote rapid diagnosis platform in mainland china, so as to achieve the goal in 2030.

Eligibility criteria:
inclusion criteria: * 1) 18 years of age and older, regardless of age or gender. * 2) the residual blood sample needs to be not less than 1ml. * 3) must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures. exclusion criteria: * 1) pregnant, lactating female and who is planning pregnancy during study period. * 2) history of tumor or other severe, life-threating diseases. * 3) samples not meet collection requirements. * 4) repeated enrollment. * 5) hcv infection has been diagnosed. * 6) recent hcv rna testing confirmed that there is no hcv infection. termination criteria: * 1) subject asked to withdraw consent. * 2) subjects may suffer adverse impact from the study at investigator's discretion.

Keywords: hepatitis c virus infection rapid diagnostic tests, rdts anti-hcv antibody hcv core antigen
anxiety symptoms in relation to use of hemp-derived, full spectrum cannabidiol (cbd)

Conditions: Generalized Anxiety Disorder

Summary: generalized anxiety disorder affects about 6.8 million adults in the united states, therefore its treatment is of major public health interest. cannabidiol (cbd) has shown promise as an effective treatment for anxiety-related symptoms while lacking the severity of adverse effects seen with other medications. given the wide availability of products containing cbd on the market today, from tinctures to coffee additives, and the undetermined potential for drug-to-drug interactions, medical supervision of cbd intake and formulation-specific clinical research is necessary. therefore this study aimed to observe the effects of a specific hemp-derived full spectrum cbd formula on anxiety-related symptoms in a group of volunteers. the investigators will examine the self-reported anxiety symptoms in relation to use of a specific cbd formulation (25mg solvent-free full spectrum cbd capsules) in a cohort of adults diagnosed with generalized anxiety disorder. this open-label, cohort study will be conducted at six clinic sites in the united states (including puerto rico) from june 2020 through october 2020. the six physicians recruited to participate in the study were each actively prescribing cbd in their practices and were actively caring for patients with anxiety symptoms. anxiety levels will be measured in enrolled participants diagnosed with generalized anxiety disorder each week for a period of eight weeks using the generalized anxiety disorder 7-item scale (gad7). participants will also be instructed to take a daily 25mg capsule of cbd. the investigators hypothesize that this formula, when carefully developed and administered by a healthcare professional, will significantly reduce anxiety symptoms.


Eligibility criteria:
inclusion criteria: * age between 21 and 85 years old. * research participants of both sexes. * good health conditions and without conditions that characterize them as belonging to the risk groups associated with adverse reactions to the product ingredients. * research participants with the potential to become pregnant may be included in the study as long as they are sexually abstinent or using a contraceptive method considered effective. * signature of the free and informed consent form. exclusion criteria: * initiation of or changes in use of medication or therapies in the past 2 weeks of start of study. * pregnancy or breastfeeding. * history of hepatic compromise with transaminases of 2 times the upper limit of normal or cirrhosis. * diagnosis of bi-polar disorder, schizophrenia or suicidal ideation. * current use of recreational marijuana, medical marijuana, or other cbd formulations. * history of any substance or alcohol abuse. * current use of high dose or extended-release narcotics. * patients diagnosed with sleep apnea.

Keywords: cannabidiol endocannabinoid system cbd cannabis anxiety generalized anxiety disorder cannabinoids endocannabinoids gad7
artoss foot and ankle surgery registry

Conditions: Arthritis Foot; Trauma Injury; Deformity; Bone

Summary: this prospective registry was designed as an observational study to ascertain how commercially available nanobone products are being used by surgeons performing foot and ankle surgery which involves bone grafting, as well as determining relevant patient outcomes.

this multicenter prospective patient registry was developed with the aim of documenting how surgeons are utilizing nanobone products in foot and ankle surgery along with relevant patient outcomes. these outcomes include radiographic measures such as fusion or graft consolidation success, instrumentation integrity, and clinical outcomes (symptom and function improvement) based on investigator and patient-based outcome assessments. the primary objective of this study is to document and analyze the use of nanobone products in foot and ankle surgery (as a stand-alone bone graft, no other local bone, autograft, bone graft substitute, or biologic product used) and determine both radiographic success and clinical outcomes. all product related adverse events will be documented, tabulated, and summarized.

Eligibility criteria:
inclusion criteria: * patient aged 18 years or older. * patient is or was diagnosed with a pathology of the foot or ankle, having failed conservative treatment, and surgeon has determined that surgery with bone graft is medically necessary. * the surgeon has determined that nanobone is or was clinically indicated. * nanobone will be or was used as a stand-alone bone graft (no autograft, other bone graft substitute, or biologic planned or used). * patient capable of understanding the content of the informed consent form * patient willing and able to participate in the registry protocol including the surgeon's standard follow-up visits and clinical evaluations. * patient who has agreed to participate in the registry by providing consent according to the applicable local law and the declaration of helsinki. exclusion criteria: * severe vascular or neurological disease * uncontrolled diabetes * severe degenerative disease (other than degenerative disc disease) * severely impaired renal function * hypercalcemia, abnormal calcium metabolism * existing acute or chronic infections, especially at the site of the operation * inflammatory bone disease such as osteomyelitis * malignant tumors * patients who are or plan to become pregnant. * uncooperative patients who cannot or will not follow post-operative instruction, including individuals who abuse drugs and/or alcohol.
cardiometabolic outcomes with light exposure during sleep

Conditions: Light

Summary: this study tested the hypothesis that acute exposure to light during nighttime sleep adversely affects cardiometabolic function.

this study tested the hypothesis that acute exposure to light during sleep adversely affects next morning glucose homeostasis and whether this effect occurs via reduced sleep quality, melatonin suppression, or sympathetic nervous system (sns) activation during sleep. twenty young adults participated in this parallel-group study design. the room light condition (n=10) included one night of sleep in dim light (\< 3 lux) followed by one night of sleep with overhead room lighting (100 lux). the dim light condition (n=10) included two consecutive nights of sleep in dim light.

Eligibility criteria:
inclusion criteria: * healthy adults * ages 18-40 years * habitual sleep duration of 6.5-8.5 hours * habitual sleep onset of 9:00 pm-1:00 am exclusion criteria: * any sleep disorder as assessed by history and screening questionnaires for obstructive sleep apnea (berlin) and excessive daytime sleepiness (ess \>12), and by psg to exclude sleep apnea (apnea hypopnea index ≥ 15), periodic leg movements (movement arousal index ≥ 15), or rem sleep behavior disorder; * history of a cognitive or neurological disorder; * history of a major psychiatric disorder, including but not limited to mood/anxiety, eating, and alcohol/substance abuse disorders; * depressed mood (beck depression inventory ii score ≥ 20); * diabetes or other endocrine disorders; * any gastrointestinal disease requiring dietary adjustment; * blindness or significant vision loss; * any unstable or serious medical conditions; * current or recent (within the past month) of psychoactive, hypnotic, stimulant or analgesic medications; * shift work or other types of self-imposed irregular sleep schedules; * obesity (body mass index \> 30 kg/m2); * history of habitual smoking (6 or more cigarettes per week) or drinking (7 or more alcoholic beverages per week) or caffeine consumption greater than 300 mg per day; * current use of light therapy; * use of any other legal or illicit substance that may affect sleep and/or appetite; * allergy to heparin. * due to the metabolic stress associated with pregnancy and breastfeeding, patients who were pregnant or breastfeeding were also excluded.

Keywords: light sleep metabolism sympathetic nervous system insulin resistance
alpha-synuclein in cerebrospinal fluid to differentiate alzheimer's disease from lewy body disease.

Conditions: "Alzheimer's Disease" and "Lewy Body Disease"

Summary: patients with memory disorders are experiencing different trends which are difficult to predict. moreover, the distinction between lewy body disease and alzheimer's disease is not easy as both diseases can present similar symptoms. nowadays, routine examinations exist and can improve the diagnosis but there are not specific enough of one of those two pathologies. lewy body disease is characterized by the presence of particular structures in patient's brain, called "lewy body", composed of a protein called "alpha-synuclein". the aim of this study is to measure the rate of alpha-synuclein in cerebrospinal fluid. this measurement could allow us to differentiate patient with alzheimer's disease from those with lewy body disease.


Eligibility criteria:
inclusion criteria: * at least 45 years of age * subject agrees to participate in the study * subject meets the criteria dubois et al., 2007. for diagnosis of probable ad. * subject with a syndromic presentation of mild cognitive impairment or mild dementia * subject has a study partner who is able to provide accurate information about the patient * subject affiliated to a social security scheme exclusion criteria: * patient who meets both ad and lewy body disease criteria * contraindications to lumbar puncture * contraindications to an mri scan * subject who is not affiliated to a social security scheme * subject under guardianship or curatorship * subject under judicial protection * subject refuses to participate in the study * subject has evidence of clinically relevant neurological disorder (fronto-temporal dementia, brain tumor, stroke, ...) that led to persistent cognitive disorders * subject has evidence of clinically relevant psychiatric disorders (schizophrenia, major depression, ...) * pregnant or attempting to become pregnant women * subject's vision and audition is sufficient for neuropsychological tests's assessment, based on the investigator's judgment.
dual-energy ct in patients with head and neck squamous cell carcinomas

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: the purpose of this study is to utilize dual-energy computed tomography (dect) to investigate changes in tumor iodine concentration in patients with head and neck squamous cell carcinomas (hnscc). dual-energy computerized tomography could easily replace a standard ct neck with the added benefit of providing functional information that would only be possible with advanced computerized tomography perfusion, magnetic resonance diffusion (mri) or positron emission tomography (pet) imaging techniques.

patients with head and/or neck tumors routinely have head and neck imaging completed with a computerized tomography scan, commonly called a ct scan. a ct scan combines a series of x-ray views that are taken from many different angles and uses computer processing to create cross-sectional images inside your body. these cross-sectional images are very thin slices, often less than 1 mm thick and allow the radiologist to examine parts of your tissue very closely. dual energy computed tomography (dect) is a fairly new technology that uses both the normal x-ray and also a second less powerful x-ray to make the images. the ottawa hospital has scanners in use that are able to take the images that oncologists typically order for patients and can also be set to obtain dect images at the same time. the purpose of this study is to investigate whether dect images can provide helpful information to better predict how the tumor will respond to treatment and the likely course of head and neck tumors.

Eligibility criteria:
inclusion criteria: * 18 years and older * untreated, histologically confirmed head and neck squamous cell carcinoma exclusion criteria: * paranasal sinus involvement of head and neck squamous cell carcinoma